CR10165A - "uso de derivados de sulfamida heterociclo benzo-fusionado para el tratamiento de depresión" - Google Patents

"uso de derivados de sulfamida heterociclo benzo-fusionado para el tratamiento de depresión"

Info

Publication number
CR10165A
CR10165A CR10165A CR10165A CR10165A CR 10165 A CR10165 A CR 10165A CR 10165 A CR10165 A CR 10165A CR 10165 A CR10165 A CR 10165A CR 10165 A CR10165 A CR 10165A
Authority
CR
Costa Rica
Prior art keywords
heterocicle
benzo
fusion
depression treatment
sulfamide derivatives
Prior art date
Application number
CR10165A
Other languages
English (en)
Inventor
L Smith-Swintosky Virginia
B Reitz Allen
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38007055&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR10165(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of CR10165A publication Critical patent/CR10165A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Pyrane Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a un método para el tratamiento de depresión , que comprende administrar a un sujeto que necesita del mismo, una cantidad terapeuticamente efectiva de uno o más derivados de heterociclo sulfamida benzofusionados de fórmula (I) y fórmula (II) como se definen en la presente; la presente invención esta dirigida a un método para el tratamiento de depresión, que incluye monoterapia y en forma alternativa, coterapia con por lo menos un antidepresivo.
CR10165A 2005-12-19 2008-07-21 "uso de derivados de sulfamida heterociclo benzo-fusionado para el tratamiento de depresión" CR10165A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75173005P 2005-12-19 2005-12-19
US11/612,249 US20070155827A1 (en) 2005-12-19 2006-12-18 Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression

Publications (1)

Publication Number Publication Date
CR10165A true CR10165A (es) 2009-01-14

Family

ID=38007055

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10165A CR10165A (es) 2005-12-19 2008-07-21 "uso de derivados de sulfamida heterociclo benzo-fusionado para el tratamiento de depresión"

Country Status (25)

Country Link
US (1) US20070155827A1 (es)
EP (1) EP1973539B1 (es)
JP (1) JP5190376B2 (es)
KR (1) KR101415532B1 (es)
CN (1) CN101336106B (es)
AT (1) ATE464895T1 (es)
AU (1) AU2006331733B2 (es)
BR (1) BRPI0620014A2 (es)
CA (1) CA2634112C (es)
CR (1) CR10165A (es)
CY (1) CY1110669T1 (es)
DE (1) DE602006013883D1 (es)
DK (1) DK1973539T3 (es)
EA (1) EA015392B1 (es)
ES (1) ES2342846T3 (es)
IL (1) IL192103A (es)
MY (1) MY148459A (es)
NI (1) NI200800176A (es)
NO (1) NO20083036L (es)
NZ (1) NZ569045A (es)
PL (1) PL1973539T3 (es)
PT (1) PT1973539E (es)
SI (1) SI1973539T1 (es)
SV (1) SV2009002861A (es)
WO (1) WO2007075751A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY147767A (en) 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
MX2007014613A (es) * 2005-05-20 2008-04-02 Johnson & Johnson Procedimiento para la preparacion de derivados de sulfamida.
US8691867B2 (en) 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US8497298B2 (en) 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
WO2007137167A2 (en) 2006-05-19 2007-11-29 Janssen Pharmaceutica N.V. Co-therapy for the treatment of epilepsy
US20090247616A1 (en) * 2008-03-26 2009-10-01 Smith-Swintosky Virginia L Use of benzo-fused heterocyle sulfamide derivatives for the treatment of anxiety
US20090247617A1 (en) * 2008-03-26 2009-10-01 Abdel-Magid Ahmed F Process for the preparation of benzo-fused heteroaryl sulfamates
WO2009120189A1 (en) * 2008-03-26 2009-10-01 Janssen Pharmaceutica N.V. Use of benzo-fused heterocycle sulfamide derivatives for the treatment of anxiety
EP2271635A1 (en) * 2008-04-29 2011-01-12 NSAB, Filial af NeuroSearch Sweden AB, Sverige Modulators of dopamine neurotransmission
KR20100135325A (ko) * 2008-04-29 2010-12-24 엔에스아베 필리알 아프 뉴로서치 스웨덴 아베 스베리게 도파민 신경전달의 조절제
AU2009242095A1 (en) * 2008-04-29 2009-11-05 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Modulators of dopamine neurotransmission
AU2009271362B2 (en) * 2008-06-23 2014-03-13 Janssen Pharmaceutica Nv Crystalline form of (2s)-(-)-N-(6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-sulfamide
US8815939B2 (en) * 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
AU2012316279A1 (en) 2011-09-29 2014-04-17 Janssen Pharmaceutica Nv Process for the preparation of sulfamide derivatives
US8895762B2 (en) 2011-09-29 2014-11-25 Janssen Pharmaceutica Nv Process for the preparation of sulfamide derivatives
KR20250077661A (ko) 2023-11-23 2025-06-02 재단법인 환동해산업연구원 항우울 및 항비만 효과를 가지는 해양생물자원 추출물 및 그 제조방법

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2527861A (en) * 1948-05-07 1950-10-31 Monsanto Chemicals Mono alkyl sulfamides
BE636655A (es) * 1962-09-14
US3318952A (en) * 1964-01-22 1967-05-09 Sandoz Ag Dibenzylsulfamides
US3383414A (en) * 1964-08-26 1968-05-14 Sandoz Ag Benzocycloalkyl sulfamides
US3539573A (en) * 1967-03-22 1970-11-10 Jean Schmutz 11-basic substituted dibenzodiazepines and dibenzothiazepines
US3621096A (en) * 1969-04-03 1971-11-16 Univ North Carolina Antidepressant method and composition for same comprising a tricyclic antidepressant and a thyroid hormone
US3689669A (en) * 1970-10-09 1972-09-05 Univ Of North Carolina The Antidepressant method and composition
US5212326A (en) * 1979-08-20 1993-05-18 Abbott Laboratories Sodium hydrogen divalproate oligomer
FR2479825A1 (fr) * 1980-04-04 1981-10-09 Fabre Sa Pierre Benzodioxanne 1,4 methoxy-2 propanolamines, leur preparation et leur application en tant que medicaments
US4513006A (en) * 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
US4804663A (en) * 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
IE58370B1 (en) * 1985-04-10 1993-09-08 Lundbeck & Co As H Indole derivatives
GB8607684D0 (en) * 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
US4831031A (en) * 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US5158952A (en) * 1988-11-07 1992-10-27 Janssen Pharmaceutica N.V. 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use
US5238945A (en) * 1989-04-11 1993-08-24 H. Lundbeck A/S Method of treating psychoses
GB8908085D0 (en) * 1989-04-11 1989-05-24 Lundbeck & Co As H New therapeutic use
US5194446A (en) * 1989-06-12 1993-03-16 A. H. Robins Company, Incorporated Compounds having one or more aminosulfaonyloxy radicals useful as pharmaceuticals
US5273993A (en) * 1989-06-12 1993-12-28 A. H. Robins Company, Incorporated Compounds having one or more aminosulfonyloxy radicals useful as pharmaceuticals
US5192785A (en) * 1989-09-03 1993-03-09 A. H. Robins Company, Incorporated Sulfamates as antiglaucoma agents
US5229382A (en) * 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
IL103172A (en) * 1991-09-19 1997-01-10 Mcneilab Inc Preparation of chlorosulfate and sulfamate derivatives of 2, 3:4, 5-bis-o-(1-methylethylidene)-beta-d-fructopyranose and (1-methylcyclohexyl) methanol
US5242942A (en) * 1992-04-28 1993-09-07 Mcneilab, Inc. Anticonvulsant fructopyranose cyclic sulfites and sulfates
US5258402A (en) * 1992-06-11 1993-11-02 Mcneil-Ppc, Inc. Imidate derivatives of pharmaceutically useful anticonvulsant sulfamates
US5312925A (en) * 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
US5384327A (en) * 1992-12-22 1995-01-24 Mcneilab, Inc. Anticonvulsant sorbopyranose sulfamates
CA2216648A1 (en) * 1995-02-15 1996-08-22 Bearsden Bio, Inc. Alkylcarboxy amino acids-modulators of the kainate receptor
JP3235448B2 (ja) * 1995-03-24 2001-12-04 ダイソー株式会社 １，４−ベンゾジオキサン誘導体の製法
US5998380A (en) * 1995-10-13 1999-12-07 New England Medical Center Hospitals, Inc. Treatment of migraine
AU1328197A (en) * 1995-12-01 1997-06-19 Synaptic Pharmaceutical Corporation Aryl sulfonamide and sulfamide derivatives and uses thereof
EP0915697B1 (en) * 1996-06-28 2002-09-18 Ortho-McNeil Pharmaceutical, Inc. Anticonvulsant sulfamate derivatives useful in treating obesity
US5753694A (en) * 1996-06-28 1998-05-19 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating amyotrophic lateral sclerosis (ALS)
US5753693A (en) * 1996-06-28 1998-05-19 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating manic-depressive bipolar disorder
EP0942752B1 (en) * 1996-08-23 2005-04-20 Algos Pharmaceutical Corporation Anticonvulsant containing composition for treating neuropathic pain
US20020015713A1 (en) * 1996-10-24 2002-02-07 Murdock Robert W. Methods and transdermal compositions for pain relief
US5935933A (en) * 1997-07-16 1999-08-10 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in treating neuropathic pain
US5760007A (en) * 1997-07-16 1998-06-02 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating neuropathic pain
AU9021298A (en) * 1997-08-15 1999-03-08 Carolyn Ann Fairbanks Agmatine as a treatment for neuropathic pain
CZ20012620A3 (cs) * 1999-01-19 2002-09-11 Ortho-Mcneil Pharmaceutical, Inc. Léčivo pro léčení histaminové cefalalgie
CA2364949A1 (en) * 1999-02-24 2000-08-31 University Of Cincinnati Use of sulfamate derivatives for treating impulse control disorders
MXPA01010218A (es) * 1999-04-08 2002-03-27 Johnson & Johnson Derivados anticonvulsivos utiles para disminuir lipidos.
US6583172B1 (en) * 1999-04-08 2003-06-24 Richard P. Shank Anticonvulsant derivatives useful in treating chronic neurodegenerative disorders
US6562865B1 (en) * 1999-08-20 2003-05-13 Ortho-Mcneil Pharmaceutical, Inc. Composition comprising a tramadol material and an anticonvulsant drug
US6322503B1 (en) * 2000-02-17 2001-11-27 G. Roger Sparhawk, Jr. Method of diagnosing, tracking, and treating depression
PT1309324E (pt) * 2000-07-07 2006-06-30 Ortho Mcneil Pharm Inc Derivados de anticonvulsivos uteis para o tratamento e prevencao do desenvolvimento de diabetes mellitus do tipo ii e da sindroma x
CA2417304A1 (en) * 2000-08-02 2002-02-07 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful for the treatment of depression
US7256184B2 (en) * 2000-10-16 2007-08-14 Rodriguez Victorio C Treatment of aging disorders in humans
EP1357908A4 (en) * 2001-01-30 2009-07-15 Merck & Co Inc "ACYLSULFAMIDES FOR THE TREATMENT OF FATIBILITY, DIABETES AND LIPID DISORDERS"
US6559293B1 (en) * 2002-02-15 2003-05-06 Transform Pharmaceuticals, Inc. Topiramate sodium trihydrate
US8637512B2 (en) * 2002-07-29 2014-01-28 Glaxo Group Limited Formulations and method of treatment
US6949518B1 (en) * 2003-06-25 2005-09-27 Pao-Hsien Chu Methods for treating macular degeneration with topiramate
MY147767A (en) * 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
AR049646A1 (es) * 2004-06-16 2006-08-23 Janssen Pharmaceutica Nv Derivados de sulfamato y sulfamida utiles para el tratamiento de la epilepsia y trastornos relacionados
MX2007002309A (es) * 2004-08-24 2007-10-08 Johnson & Johnson Novedosos derivados de heteroarilsulfamida benzofusionados utiles como agentes anticonvulsivos.
US20060276528A1 (en) * 2004-08-24 2006-12-07 Abdel-Magid Ahmed F Novel benzo-fused heteroaryl sulfamide derivatives useful as anticonvulsant agents
KR20080009295A (ko) * 2005-04-22 2008-01-28 와이어쓰 벤조디옥산 및 벤조디옥솔란 유도체 및 이의 용도
MX2007014613A (es) * 2005-05-20 2008-04-02 Johnson & Johnson Procedimiento para la preparacion de derivados de sulfamida.
US8716231B2 (en) * 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
AR058389A1 (es) * 2005-12-19 2008-01-30 Janssen Pharmaceutica Nv Uso de derivados heterociclicos benzo-fusionados de sulfamida para el tratamiento de la obesidad
US20070155824A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives for disease modification / epileptogenesis
US8497298B2 (en) * 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US8937096B2 (en) * 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
KR101174777B1 (ko) * 2005-12-27 2012-08-20 엘지디스플레이 주식회사 패턴형성방법 및 그를 이용한 액정표시소자 제조방법
WO2007137167A2 (en) * 2006-05-19 2007-11-29 Janssen Pharmaceutica N.V. Co-therapy for the treatment of epilepsy
US20070293476A1 (en) * 2006-05-19 2007-12-20 Smith-Swintosky Virginia L Co-therapy for the treatment of epilepsy and related disorders
WO2009089210A1 (en) * 2008-01-07 2009-07-16 Janssen Pharmaceutica N. V. Preparation of sulfamide derivatives
US20090247618A1 (en) * 2008-03-26 2009-10-01 Ballentine Scott A Process for preparation of benzo-fused heteroaryl derivatives
US20090247617A1 (en) * 2008-03-26 2009-10-01 Abdel-Magid Ahmed F Process for the preparation of benzo-fused heteroaryl sulfamates
AU2009271362B2 (en) * 2008-06-23 2014-03-13 Janssen Pharmaceutica Nv Crystalline form of (2s)-(-)-N-(6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-sulfamide
US8815939B2 (en) * 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
AU2012316279A1 (en) * 2011-09-29 2014-04-17 Janssen Pharmaceutica Nv Process for the preparation of sulfamide derivatives
US8895762B2 (en) * 2011-09-29 2014-11-25 Janssen Pharmaceutica Nv Process for the preparation of sulfamide derivatives

Also Published As

Publication number Publication date
KR101415532B1 (ko) 2014-07-04
IL192103A (en) 2012-10-31
ES2342846T3 (es) 2010-07-15
MY148459A (en) 2013-04-30
EP1973539A1 (en) 2008-10-01
CN101336106B (zh) 2012-09-05
ATE464895T1 (de) 2010-05-15
EP1973539B1 (en) 2010-04-21
EA200870090A1 (ru) 2008-12-30
JP2009520034A (ja) 2009-05-21
AU2006331733B2 (en) 2013-01-10
EA015392B1 (ru) 2011-08-30
CN101336106A (zh) 2008-12-31
CA2634112C (en) 2014-08-05
SV2009002861A (es) 2009-02-23
KR20080089414A (ko) 2008-10-06
JP5190376B2 (ja) 2013-04-24
NI200800176A (es) 2012-05-28
NO20083036L (no) 2008-09-05
PL1973539T3 (pl) 2010-09-30
DE602006013883D1 (de) 2010-06-02
BRPI0620014A2 (pt) 2011-10-25
DK1973539T3 (da) 2010-08-02
WO2007075751A1 (en) 2007-07-05
HK1125040A1 (en) 2009-07-31
CA2634112A1 (en) 2007-07-05
PT1973539E (pt) 2010-05-25
CY1110669T1 (el) 2015-06-10
US20070155827A1 (en) 2007-07-05
IL192103A0 (en) 2009-08-03
SI1973539T1 (sl) 2010-08-31
NZ569045A (en) 2011-05-27
AU2006331733A1 (en) 2007-07-05

Similar Documents

Publication Publication Date Title
CR10165A (es) "uso de derivados de sulfamida heterociclo benzo-fusionado para el tratamiento de depresión"
NI200800169A (es) Uso de derivados de sulfamidas heterocíclicas benzo-fusionadas para el tratamiento del dolor
CR10166A (es) Uso de derivados de sulfamida heterociclo benzo-fusionado para el tratamiento del trastorno bipolar y mania
CR10164A (es) Uso de derivados de sulfamida heterociclica benzo-fusionada para el tratamiento de obesidad
CR10172A (es) Uso de derivados de sulfamida heterociclica benzo-fusionada para el tratamiento de abuso y adicción de sustancias
PA8740901A1 (es) Compuestos organicos
UY30158A1 (es) Uso de derivados de benzo-heteroaril sulfamida para el tratamiento del dolor
CL2007003520A1 (es) Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso para el tratamiento profilactico o terapeutico del cancer.
PA8637201A1 (es) Difenilimidazopirimidina e-imidazol aminas como inhibidores de la b-secretasa
NI200900073A (es) Compuestos de carbamato para su uso en el tratamiento de la depresión.
CL2011001026A1 (es) Uso de pimobedan para preparar un medicamento util en el tratamiento de cardiomiopatia hipertrofica en un gato.
ECSP11011101A (es) Compuestos cicloundecadepsipéptidos y el uso de dichos compuestos como un medicamento
AR058173A1 (es) Uso de sdf-1 para el tratamiento y/o prevencion de enfermedades neurologicas
ES2570158T3 (es) Tratamiento de la isquemia de extremidades
UY29417A1 (es) Agentes endoparasiticidas
UY30040A1 (es) Uso de derivados heterociclicos benzo-fusionados de sulfamida para el tratamiento de la depresion
UY30039A1 (es) Uso de derivados heterociclicos benzo-fusionados para el tratamiento de la mania y el trastorno bipolar
UY30160A1 (es) Uso de derivados de sulfamida heterociclica fusionada con benzo para el tratamiento de migrana
UY30038A1 (es) Uso de derivaods heterociclicos benzo-fusionados de sulfamida para el tratamiento de adiccion y abuso de sustancias
UY30034A1 (es) Uso de derivados heterociclicos benzo-fusionados de sulfamida para el tratamiento del dolor
UY30156A1 (es) Uso de derivados de benzo-heteroarilsulfamida para el tratamiento de la migrana
CO6491023A2 (es) Uso de la combinacion de teriflunomida e interferon beta para el tratamiento de la esclerosis multiple
UY30152A1 (es) Uso de derivados benzo-heteroaril sulfamida para el tratamiento de la depresion
UA100552C2 (ru) Применение гетероциклических бензопроизводных сульфамида для лечения тревожных расстройств
UY30155A1 (es) Uso de derivados de benzo-heteroaril sulfamida para el tratamiento de mania y trastorno bipolar

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)